REYON Pharmaceutical Company Description
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines.
The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators.
It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study.
In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer.
REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Country | South Korea |
Founded | 1955 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 448 |
Contact Details
Address: Building A, Mirae Asset Tower Seoul South Korea | |
Phone | 82 2 793 5557 |
Website | reyonpharm.co.kr |
Stock Details
Ticker Symbol | 102460 |
Exchange | Korea Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | KRW |
ISIN Number | KR7102460003 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Yong-Hwan Yoo | President, Chief Executive Officer and Representative Director |
Soon-Ock Jung | Chairman and Chief Executive Officer |
Hung-Muk Choi | Executive Director |